Helidac Therapy is highly effective in eradicating H. pylori bacteria, which live in the stomach and upper intestine. These bacteria are associated with most cases of duodenal ulcers, which afflict three million Americans. Some health care professionals believe this packaging is a critically-important addition. Alan Cutler, M.D., one of the nation's leading H. pylori researchers and director of gastroenterology research at Sinai Hospital in Detroit, said physicians often find some patients have a hard time complying with multi-drug regimens. All ulcer bacterial eradication therapies, including Helidac Therapy, require multiple drugs, some of which need to be taken up to four times each day.
Medication only works if it's taken properly.
This study also identified that up to 10 percent of hospital admissions and 20 percent of nursing home patient admissions are associated with non-compliance. This kit incorporated the most successful ideas from its patient, physician and pharmacist research. There is also a patient booklet which provides information about duodenal ulcers and Helidac Therapy. As with any prescription drug, however, Helidac Therapy is not for all patients. Helidac Therapy is contraindicated in pregnant or nursing women, pediatric patients and patients with renal or hepatic impairment, and in those with known hypersensitivity to bismuth subsalicylate, metronidazole or other nitromidazole derivatives, or any of the tetracyclines.